STOCK TITAN

Chromadex Corp - CDXC STOCK NEWS

Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.

About Chromadex Corp

Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.

Business Model and Core Segments

Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:

  • Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
  • Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
  • Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.

Research and Innovation

At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.

Market Position and Competitive Differentiation

Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.

Commitment to Transparency and Quality

Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.

Integrating Science and Consumer Wellness

The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on Monday, February 12, 2024, at 11:00 AM PST. The event will feature the latest investor presentation by CEO Rob Fried and CFO Brianna Gerber, followed by a live Q&A. Registration is limited, but the replay will be available on ChromaDex’s website. For more information, visit www.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) CEO and CFO will be participating in the Lytham Partners 2024 Investor Select Conference for virtual one-on-one meetings. The event is scheduled for Thursday, February 1, 2024. For more information, visit www.chromadex.com and www.investors.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the launch of Tru Niagen, its patented nicotinamide riboside (NR) supplement, to support the US Military Special Operations Forces. The initiative includes an exclusive program that offers Tru Niagen products to active and veteran Military Service Members, reflecting ChromaDex's commitment to the health and well-being of those who serve the Nation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
Rhea-AI Summary
Neurohacker Collective has launched Qualia NAD+ featuring ChromaDex's patented Nicotinamide Riboside (NR) as an NAD+ supplement to boost NAD+ levels in aging Americans. The pilot study resulted in 95% of participants rating the experience as 'excellent' to 'good.' Qualia NAD+ is positioned to become a category leader in NAD+ supplementation, leveraging Niagen, the FDA-notified form of NR, backed by two Nobel Prize winners and over 25 human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
partnership
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) shares results from a new study on the safety and benefits of high-dose nicotinamide riboside (NR) supplementation for individuals with Parkinson’s disease. The study demonstrated that supplementing individuals with PD with high-dose Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, and was associated with a significant clinical improvement. This marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the results of a phase II clinical study on Niagen NR, demonstrating up to fourfold increase in NAD+ levels, improved coordination and eye movement in Ataxia Telangiectasia (AT) patients. The study is the longest Niagen NR clinical trial to date, spanning two years, and showcases that long-term Niagen NR is safe and well tolerated. The promising results highlight the potential of Niagen NR in supporting brain health and cognition, indicating a potential therapeutic strategy for AT patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
Rhea-AI Summary
ChromaDex Corporation (NASDAQ: CDXC) to Participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
conferences
-
Rhea-AI Summary
ChromaDex Corp. (NASDAQ: CDXC) announced third-quarter 2023 financial results, including $19.5 million in net sales, a 61.4% gross margin, and a $1.0 million net loss. Key highlights are Tru Niagen® sales growth and a positive Adjusted EBITDA of $0.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
-
Rhea-AI Summary
ChromaDex Corp. launches Tru Niagen Pro 1,000mg, a clinical strength supplement proven to boost NAD+ levels by up to 150% in as little as three weeks. The product features 1,000mg of Niagen, a superior quality NAD+ precursor. It is recommended by physicians and used by pro-athletes. Tru Niagen Pro 1,000mg is Certified for Sport® by NSF International.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 8, 2023, at 4:30 p.m. ET to discuss its financial results for the third quarter of 2023. The results will be reported in a press release after the close of regular stock market trading hours on the same day. The conference call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings

FAQ

What is the current stock price of Chromadex (CDXC)?

The current stock price of Chromadex (CDXC) is $7.87 as of March 19, 2025.

What is the market cap of Chromadex (CDXC)?

The market cap of Chromadex (CDXC) is approximately 594.5M.

What is Chromadex Corp's primary focus?

Chromadex Corp focuses on healthy aging through advanced scientific research, particularly in the area of NAD+ and its precursors, translating this research into practical nutraceutical products.

How does Chromadex generate its revenue?

The company generates revenue primarily through its three segments: direct-to-consumer products, the development and licensing of proprietary ingredients, and the provision of analytical reference standards and services.

What makes Chromadex's research unique?

Chromadex’s approach is distinguished by its collaborative partnerships with leading research institutions, which allows it to delve deep into the science of aging and develop innovative, validated ingredients.

What is the significance of nicotinamide riboside (NR) for Chromadex?

Nicotinamide riboside (NR) is a key ingredient developed by Chromadex, acting as a precursor to NAD+. Its role in supporting cellular health underscores the company’s commitment to leveraging advanced science for healthy aging.

In which segments does Chromadex operate?

Chromadex operates across three segments: Consumer Products, which focuses on end-user nutraceutical products; Ingredients, which develops and licenses innovative ingredients; and Analytical Reference Standards and Services, ensuring rigorous quality control.

How does Chromadex ensure the quality and safety of its products?

The company employs rigorous quality control processes and analytical methods across all its segments to ensure that all products and ingredients meet high standards of efficacy and safety.

How is Chromadex positioned within the competitive landscape?

Chromadex is well-positioned due to its integrated approach combining research, product innovation, and quality assurance, which differentiates it from other companies in the nutraceutical and bioscience industries.

What are the key benefits of Chromadex's integrated business model?

The integrated business model allows Chromadex to seamlessly transition from cutting-edge research to market-ready products, ensuring that scientific insights are effectively translated into tangible health benefits.
Chromadex Corp

Nasdaq:CDXC

CDXC Rankings

CDXC Stock Data

594.49M
50.70M
34.79%
30%
2.72%
Biotechnology
Medicinal Chemicals & Botanical Products
Link
United States
LOS ANGELES